HUTCHMED (China) Limited
HUTCHMED (China) Limited (HCM): 49 pipeline candidates · 1 upcoming catalyst · ~63 mo cash runway · 8 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
63.2 months
D/E 0.41
Lead: Phase 3
49 candidates
1 upcoming, next in ~712d
N/A
A transparent, data-derived signal for HUTCHMED (China) Limitedacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.7B
Cash
$71.3M
Quarterly Burn
$64.7M
Runway
63.2 mo
Revenue
$548.5M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (49 candidates)
| Drug | Phase |
|---|---|
| 100 µci [14c] hmpl-306 | Phase 1 |
| 100 µci [14c] hmpl-306 | Phase 1 |
| anti-pd-1/l1 | Phase 2 |
| fruquintinib in combination with sintilimab | Phase 3 |
| hmpl-306 | Phase 3 |
| hmpl-306 | Phase 3 |
| hmpl-306 regimen | Phase 3 |
| hmpl-306 regimen | Phase 3 |
| hmpl-453 | Phase 1 |
| hmpl-453 | Phase 3 |
Showing 10 of 49 candidates. Sign up for full pipeline.
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
50
Total value held
$46.4M
| Holder | Shares | Value |
|---|---|---|
| schroder investment management group | 1,477,494 | $22.1M |
| state street corp | 304,829 | $4.6M |
| aia group ltd | 291,229 | $4.4M |
| m&g plc | 255,468 | $3.8M |
| renaissance technologies llc | 132,062 | $2.0M |
| bnp paribas financial markets | 106,504 | $1.6M |
| jane street group, llc | 76,514 | $1.1M |
| tidal investments llc | 67,385 | $1.0M |
| dimensional fund advisors lp | 55,969 | $837K |
| xy capital ltd | 48,394 | $724K |
Showing top 10 of 50 institutional holders of HUTCHMED (China) Limited. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in HUTCHMED (China) Limited's pipeline?
HUTCHMED (China) Limited (HCM) has 49 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is HUTCHMED (China) Limited's lead drug candidate?
HUTCHMED (China) Limited's most advanced tracked candidate is 100 µci [14c] hmpl-306 (Phase 1) for Healthy Participants.
What is HUTCHMED (China) Limited's next catalyst?
HUTCHMED (China) Limited's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Multicenter, Randomized, Double-blind, Phase III Clinical Study to Evaluate the Efficacy and Safet" — expected May 30, 2028.
What is HUTCHMED (China) Limited's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, HUTCHMED (China) Limited has approximately 63.2 months of cash runway.
What is HUTCHMED (China) Limited's market capitalization?
HUTCHMED (China) Limited's market capitalization is approximately $1.7B.
Get the full picture on HUTCHMED (China) Limited
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.